Friday, June 19, 2026

Patent directory · USPTO A61K / A61P

Browse patents

Browse 30,257 pharma-relevant patents (US A61K/A61P) linked to tracked companies, drugs, and pipeline programs.

Patents indexed 30,257
Companies 1,771
Drugs linked 4,798

Quick answer

NovaPharmaNews indexes 30,257 US pharmaceutical patents from USPTO PatentsView (CPC A61K/A61P), cross-linked to company assignees, drug INN profiles, and pipeline programs. Search by patent number, applicant, title, or CPC code — or use facet hubs for expiring patents, assignees, and therapeutic areas.

Patent results

Page 346 of 1,261
  1. US 11000520

    Buprenorphine dosing regimens

    Indivior UK Limited · Granted May 11, 2021 · Expires May 6, 2041

    granted
  2. US 11000562

    Use of isolated fractions of mastic gum for treating optic neuropathy

    REGENERA PHARMA LTD. · Granted May 11, 2021 · Expires May 6, 2041

    granted
  3. US 11000493

    Solid solution compositions and use in chronic inflammation

    Infirst Healthcare Limited · Granted May 11, 2021 · Expires May 6, 2041

    granted
  4. US 11000570

    Isoform Nell-1 peptide

    The Regents of the University of California · Granted May 11, 2021 · Expires May 6, 2041

    granted
  5. US 11000502

    Antimicrobial compositions comprising copper-hydroxypyrone complexes

    United Kingdom Research and Innovation · Granted May 11, 2021 · Expires May 6, 2041

    granted
  6. US 11000409

    Devices and methods for slurry generation

    MIRAKI INNOVATION THINK TANK LLC · Granted May 11, 2021 · Expires May 6, 2041

    granted
  7. US 2021128573

    DOSING REGIMENS FOR USE IN TREATING MYELOFIBROSIS AND MPN-RELATED DISORDERS WITH NAVITOCLAX

    ABBVIE INC [US] · Granted May 6, 2021 · Expires May 1, 2041

    granted
  8. US 10993936

    Method of treating one or more symptoms of pulmonary fibrosis by administering inhibitors of nicotinamide phosphoribotransferase

    Arizona Board of Regents on Behalf of the University of Arizona · Granted May 4, 2021 · Expires Apr 29, 2041

    granted
  9. US 10995156

    Acid-degradable and bioerodible modified polyhydroxylated materials

    The Regents of the University of California · Granted May 4, 2021 · Expires Apr 29, 2041

    granted
  10. US 10994014

    Bacterially derived, intact minicells for delivery of therapeutic agents to brain tumors

    EnGeneIC Molecular Delivery Pty Ltd · Granted May 4, 2021 · Expires Apr 29, 2041

    granted
  11. US 10993959

    Methods and compositions for increasing the suppressive function of regulatory T-cells (Tregs)

    Regents of the University of Minnesota · Granted May 4, 2021 · Expires Apr 29, 2041

    granted
  12. US 10993948

    RNA polymerase I inhibitors and uses thereof

    TEL HASHOMER MEDICAL RESEARCH INFRASTRUCTURE AND SERVICES LTD. · Granted May 4, 2021 · Expires Apr 29, 2041

    granted
  13. US 10993419

    Genetically modified cells, tissues, and organs for treating disease

    Regents of the University of Minnesota · Granted May 4, 2021 · Expires Apr 29, 2041

    granted
  14. US 10995100

    Bicyclic heterocyclyl derivatives as IRAK4 inhibitors

    Aurigene Discovery Technologies Limited · Granted May 4, 2021 · Expires Apr 29, 2041

    granted
  15. US 10995061

    SPAK kinase inhibitors as neuroprotective agents

    United States Government as represented by the Department of Veterans Affairs · Granted May 4, 2021 · Expires Apr 29, 2041

    granted
  16. US 10995071

    Method for producing a polymorphic form of 3-[5-amino-4-(3-cyanobenzoyl)-pyrazol-1-yl]-N-cyclopropyl-4-methylbenzamide

    MEREO BIOPHARMA 1 LIMITED · Granted May 4, 2021 · Expires Apr 29, 2041

    granted
  17. US 10995336

    Serpina1 iRNA compositions and methods of use thereof

    Alnylam Pharmaceuticals, Inc. · Granted May 4, 2021 · Expires Apr 29, 2041

    granted
  18. US 10995317

    NK cells exhibiting an adaptive phenotype and methods for preparing and for using

    Regents of the University of Minnesota · Granted May 4, 2021 · Expires Apr 29, 2041

    granted
  19. US 10995150

    Methods for inhibiting atherosclerosis by administering an anti-PCSK9 antibody

    REGENERON PHARMACEUTICALS, INC. · Granted May 4, 2021 · Expires Apr 29, 2041

    granted
  20. US 10995328

    Materials and methods for treatment of autosomal dominant cone-rod dystrophy

    CRISPR THERAPEUTICS AG · Granted May 4, 2021 · Expires Apr 29, 2041

    granted
  21. US 10995146

    Methods of treating severe insulin resistance by interfering with glucagon receptor signaling

    REGENERON PHARMACEUTICALS, INC. · Granted May 4, 2021 · Expires Apr 29, 2041

    granted
  22. US 10995087

    Crystal form of URAT1 inhibitor, and preparation method therefor

    Medshine Discovery Inc. · Granted May 4, 2021 · Expires Apr 29, 2041

    granted
  23. US 10995068

    Synthetic sphingolipid-like molecules, drugs, methods of their synthesis and methods of treatment

    The Regents of the University of California · Granted May 4, 2021 · Expires Apr 29, 2041

    granted
  24. US 10995335

    RNAi agents and compositions for inhibiting expression of angiopoietin-like 3 (ANGPTL3), and methods of use

    Arrowhead Pharmaceuticals, Inc. · Granted May 4, 2021 · Expires Apr 29, 2041

    granted

Frequently asked questions

What patents are included in this directory?

We index 30,257 published US pharma-relevant patents filtered to CPC classes A61K and A61P, with assignee links to our company directory where a match exists.

How do I search for a patent?

Use the search box to match patent number, title, applicant name, or CPC classification (e.g. A61K). For cross-entity queries spanning news and drugs, use the global search.

How is this different from the patent intelligence dashboard?

The dashboard at /patents highlights expirations, recent grants, and assignee rankings. Browse is the full paginated directory with search — best for looking up a specific filing or applicant portfolio slice.